Preeclampsia Prevention and Management

Preeclampsia Prevention: Risk Levels, Risk Factors, and Recommendations

1. High-Risk Factors

• History of preeclampsia, especially if it was severe or resulted in an adverse outcome

• Multifetal gestation (twins, triplets, etc.)

• Chronic hypertension

• Type 1 or Type 2 diabetes

• Renal disease

• Autoimmune disease (e.g., systemic lupus erythematosus, antiphospholipid syndrome)

Recommendation:

• Low-dose aspirin is recommended if a patient has one or more high-risk factors.
  

2. Moderate-Risk Factors

• Nulliparity (first pregnancy)

• Obesity (BMI > 30 kg/m²)

• Family history of preeclampsia (mother or sister)

• Sociodemographic factors (e.g., African American race, low socioeconomic status)

• Maternal age ≥ 35 years

• Personal history factors:

  • Low birth weight or previously small-for-gestational-age infant

  • Previous adverse pregnancy outcome

  • Pregnancy interval of more than 10 years

• Previous uncomplicated full-term delivery (some guidelines categorize this differently; it appears here as listed in the source)

Recommendation:

• If a patient has more than one moderate-risk factor, consider low-dose aspirin.

• Having only one moderate-risk factor typically does not warrant aspirin prophylaxis on its own, unless otherwise directed by local protocols or clinical judgment.
  

3. Low-Risk Factors

• No specific medical or obstetric risk factors beyond general population baseline

• Includes those whose history does not match any of the high-risk or multiple moderate-risk categories

Recommendation:

• Low-dose aspirin prophylaxis is not recommended for those at low risk based on current standard guidelines.
  

Additional Notes and Clarifications

• Risk Factors listed here are primarily those that can be determined from a woman’s medical and obstetric history.

• Clinical measures (e.g., abnormal uterine artery Doppler, certain serum biomarkers) are not included in this simplified table but are sometimes used in specialized practices or research settings to further refine risk.

• Incidence Rates: Women with one or more high-risk factors have an estimated incidence of preeclampsia of ~8% or higher, making aspirin prophylaxis a clear recommendation.

• A combination of multiple moderate-risk factors can elevate the overall risk sufficiently to consider prophylaxis.
  

Key Takeaway

• Low-dose Aspirin (typically 81 mg daily) initiated in the late first or early second trimester (around 12–16 weeks) is recommended for women at high risk of preeclampsia or those with multiple moderate-risk factors.

• This prophylactic strategy has been shown to reduce both the incidence and severity of preeclampsia and its related complications.

• The latest recommended start for low-dose aspirin is generally by 28 weeks, as initiating beyond this gestational age does not allow enough time for a meaningful prophylactic effect.

• Discontinuation of low-dose aspirin typically occurs at 36 weeks of gestation or 1 week before a scheduled cesarean delivery (e.g., if a C/S is planned at 35 weeks, aspirin would be stopped at 34 weeks). This timing helps reduce potential bleeding risks around delivery.

  
  

---

Oral Antihypertensive Medications in Pregnancy

Drug	Dosage	Comments
Labetalol	- Total Daily Dose: 200–2,400 mg/day in 2–3 divided doses  - Common Initial Dose: 100–200 mg twice daily	- Potential bronchoconstrictive effects. - Avoid in women with asthma, preexisting myocardial disease, decompensated cardiac function, heart block, or bradycardia.
Nifedipine (Extended-Release)	- Total Daily Dose: 30–120 mg/day - Common Initial Dose: 30–60 mg once daily (extended-release form)	- Do not use sublingual form (associated with unpredictable blood pressure drops). - Immediate-release nifedipine is generally reserved for severe, acutely elevated BP in hospitalized patients. - Should be avoided in tachycardia because of potential reflex sympathetic response.
Methyldopa	- Total Daily Dose: 500–3,000 mg/day in 2–4 divided doses  - Common Initial Dose: 250 mg twice or three times daily	- Extensive safety data available up to 7 years of age in offspring. - May be less effective than other agents in controlling severe hypertension. - Use can be limited by side effects: sedation, depression, dizziness.
Hydrochlorothiazide	- Total Daily Dose: 12.5–50 mg/day	- Generally considered second-line or third-line therapy. - Loop diuretics are more commonly used if diuresis is needed in specific circumstances, but thiazides can be an option for chronic hypertension.

Additional Notes

1. Labetalol and Nifedipine (extended-release) are commonly favored as first-line agents for chronic hypertension in pregnancy, particularly when blood pressures are consistently above recommended treatment thresholds.

2. Methyldopa has a long history of use and extensive safety data, but its side effect profile makes it less common in modern practice.

3. Hydrochlorothiazide is often viewed as second- or third-line; diuretics are typically used cautiously in pregnancy unless there is a specific indication (e.g., heart failure) because pregnancy is a volume-expanded state.

4. Always individualize treatment based on maternal comorbidities, patient tolerance, and blood pressure goals in consultation with obstetric and maternal-fetal medicine guidelines.

   
   

---

Below is a reorganized summary of seizure prophylaxis in severe preeclampsia, focusing on magnesium sulfate (MgSO₄). The information has been consolidated for clarity and corrected from its original left-to-right format.

1. Rationale for MgSO₄

• Drug of Choice: Magnesium sulfate is the preferred agent for preventing seizures (eclampsia) in women with preeclampsia with severe features.

• Benefits: Reduces seizure risk (relative risk ~0.41) and lowers incidence of placental abruption (relative risk ~0.64).

• Timing: Begin MgSO₄ infusion promptly once a patient is diagnosed with preeclampsia with severe features.
  

2. Magnesium Sulfate Dosing (IV Route)

• Loading Dose:

  • 4–6 g IV over 20–30 minutes.

• Maintenance Infusion:

  • 1–2 g/hour (adjust according to clinical and laboratory parameters).

Sample IV Orders

1. Loading Dose

   • 10% MgSO₄ 40 mL (4 g) IV loading over 30 min

2. Maintenance Infusion

   • 50% MgSO₄ 80 mL + 5% Dextrose Water (DW) 920 mL = total 1,000 mL

   • Infuse at 50 mL/hour → 2 g/hour of MgSO₄
     

3. Therapeutic and Toxic Ranges

Below is a simplified, typical reference for serum magnesium levels:

Serum Mg Level	mEq/L	mg/dL	Clinical Effect
Therapeutic range	4–7	5–9	Optimal anticonvulsant effect
Loss of patellar reflex	~10	~12	Early sign of toxicity
Respiratory paralysis	~12	~15	Severe toxicity
Cardiac arrest	~25	~30	Extreme toxicity (rare with close monitoring)

Note: Conversions (mmol/L vs. mEq/L vs. mg/dL) vary slightly by reference source, but the above ranges are commonly accepted approximations.

4. Monitoring During MgSO₄ Infusion

1. Urine Output

   • Place a Foley catheter if needed.

   • Maintain >0.5 mL/kg/hour to ensure adequate renal clearance of magnesium.

2. Deep Tendon Reflex

   • Check patellar reflex (knee jerk) to detect early hyporeflexia or areflexia.

3. Respiratory Rate

   • Aim for ≥14 breaths/minute. A declining rate (<12–14) suggests possible toxicity.

4. Serum Magnesium

   • Routine levels may not be required in normal renal function, but frequent measurement (e.g., every 4 hours) is advised if there is renal impairment or any concern for toxicity.
     

5. Magnesium Toxicity Management

1. If Serum Mg >8 mEq/L but No Clinical Symptoms:

   • Stop the MgSO₄ infusion.

   • Check serum Mg every 2 hours.

   • Once Mg level <7 mEq/L, consider restarting at a reduced rate.

2. If Clinical Signs of Toxicity Appear (e.g., depressed respirations, loss of deep tendon reflexes, confusion):

   • Discontinue MgSO₄ immediately and measure serum Mg every 2 hours.

   • Respiratory Depression: May require endotracheal intubation and ventilatory support.

   • Enhance Renal Excretion: Consider IV furosemide if adequate urine output.

   • Antidote: 10% Calcium gluconate 10 mL IV given over 3 minutes to counteract magnesium’s neuromuscular blockade.
     

Key Points

• Start MgSO₄ as soon as a diagnosis of severe preeclampsia is made.

• Maintain therapeutic levels to prevent seizures while minimizing toxicity.

• Vigilant monitoring (reflexes, urine output, respiratory rate) is crucial.

• Prompt dose adjustment or discontinuation is essential at the first sign of toxicity or if serum levels become excessive.

This protocol helps ensure effective seizure prophylaxis in severe preeclampsia and reduces maternal complications while safeguarding against magnesium overdose.

---

Conclusions

• Delivery remains the only definitive cure for preeclampsia.

• Magnesium sulfate (MgSO₄) is the proven first-choice medication to prevent and treat severe preeclampsia and eclampsia.

• Initial management priorities include:

  • Anticonvulsant therapy (MgSO₄)

  • Blood pressure control

  • Fetal monitoring and labor induction as needed

  • Electrolyte and maternal status checks to prevent complications

ลดความดัน ป้องกันชัก induction หมั่นดูเด็ก เช็คอีไลต์ให้ป้องกัน (ภาวะแทรกซ้อน)